Xenon Pharmaceuticals Inc.
XENENASDAQHealthcare● Active
$51.48
$-0.26(-0.49%)
Market Cap$4.1B
P/E Ratio—
52W High$63.95
52W Low$30
Xenon Pharmaceuticals Inc. (XENE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
XENE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.17
Est. -$1.17 · +0.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
XENE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$1.16 | — | — | — | $0.00B | — |
| — Q2 FY2026 | May 7, 2026 | -$1.17 | -$1.17 | +0.0% | — | $0.00B | — |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$1.20 | -$1.31 | -9.2% | — | $-0.00B | — |
| — Q4 FY2025 | Nov 3, 2025 | -$1.16 | -$1.15 | +0.9% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$1.03 | -$1.07 | -3.9% | — | — | — |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.94 | -$0.83 | +11.7% | $0.01B | $0.00B | +293.4% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.89 | -$0.84 | +5.6% | — | $0.00B | — |
| — Q4 FY2024 | Nov 12, 2024 | -$0.82 | -$0.81 | +0.7% | — | $0.00B | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$1.16
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026
EPS Actual
-$1.17
EPS Est.
-$1.17
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$1.31
EPS Est.
-$1.20
EPS Surpr.
-9.2%
Revenue
—
Q4 FY2025
Nov 3, 2025
EPS Actual
-$1.15
EPS Est.
-$1.16
EPS Surpr.
+0.9%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$1.07
EPS Est.
-$1.03
EPS Surpr.
-3.9%
Revenue
—
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.83
EPS Est.
-$0.94
EPS Surpr.
+11.7%
Revenue
$0.01B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.84
EPS Est.
-$0.89
EPS Surpr.
+5.6%
Revenue
—
Q4 FY2024
Nov 12, 2024
EPS Actual
-$0.81
EPS Est.
-$0.82
EPS Surpr.
+0.7%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.44 | $-1.44 | $-1.44 | 4 |
| Q3 FY2027 | $-1.33 | $-1.33 | $-1.33 | 4 |
| Q2 FY2027 | $-1.33 | $-1.33 | $-1.33 | 4 |
| Q1 FY2027 | $-1.29 | $-1.29 | $-1.29 | 4 |
| Q4 FY2026 | $-1.22 | $-1.22 | $-1.22 | 4 |
| Q3 FY2026 | $-1.34 | $-1.18 | $-1.02 | 10 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 15 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 8 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 8 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 15 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +0.0% | $58.59 | $56.00 | -4.42% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -9.2% | $44.58 | $44.92 | +0.76% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +0.9% | $41.92 | $41.12 | -1.91% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -3.9% | $33.43 | $34.11 | +2.03% |
| ▲ Q2 FY2025 | May 12, 2025 | +11.7% | $35.02 | $35.85 | +2.37% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +5.6% | $39.10 | $38.31 | -2.02% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +0.7% | $44.07 | $43.39 | -1.54% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -4.2% | $40.37 | $41.01 | +1.59% |
Q2 FY2026-4.42%
Report Date
May 7, 2026
EPS Beat/Miss
+0.0%
Price Before
$58.59
Price After
$56.00
Q1 FY2026+0.76%
Report Date
Feb 26, 2026
EPS Beat/Miss
-9.2%
Price Before
$44.58
Price After
$44.92
Q4 FY2025-1.91%
Report Date
Nov 3, 2025
EPS Beat/Miss
+0.9%
Price Before
$41.92
Price After
$41.12
Q3 FY2025+2.03%
Report Date
Aug 11, 2025
EPS Beat/Miss
-3.9%
Price Before
$33.43
Price After
$34.11
Q2 FY2025+2.37%
Report Date
May 12, 2025
EPS Beat/Miss
+11.7%
Price Before
$35.02
Price After
$35.85
Q1 FY2025-2.02%
Report Date
Feb 27, 2025
EPS Beat/Miss
+5.6%
Price Before
$39.10
Price After
$38.31
Q4 FY2024-1.54%
Report Date
Nov 12, 2024
EPS Beat/Miss
+0.7%
Price Before
$44.07
Price After
$43.39
Q3 FY2024+1.59%
Report Date
Aug 8, 2024
EPS Beat/Miss
-4.2%
Price Before
$40.37
Price After
$41.01
Avg Beat Reaction-1.50%
Avg Miss Reaction+1.46%
Beat Rate5 / 8 quarters
Largest Move-4.42% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: XENE ends December
Xenon Pharmaceuticals Inc. (XENE) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.17 (in line with the analyst consensus of $-1.17). The next XENE earnings date is expected around September 1, 2026.
Each quarter, investors track XENE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. XENE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
XENE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
XENE earnings · 4 questionsXenon Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. XENE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; XENE historically reports after market close (AMC).
XENE earnings datewhen is XENE earningsXENE next earnings datewhen does XENE report earningsXENE earnings calendar
▸ Source: FMP · Xenon Pharmaceuticals Inc. SEC filings · US GAAP · Xenon Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026